... with proven overall survival (OS) benefit in metastatic breast cancer (MBC), which may also enhance intratumoral vascular remodeling. Durvalumab, a humanized monoclonal antibody, targets the programmed cell death ligand-1 (PD-L1) receptor. This study sought to determine the maximum tolerated dose...

... who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK. Methods: Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included the hormone-receptor status, histological diagnosis, age, prior chemotherapy...

...Sufana Shikdar; Spencer Hall; Brandon Taylor; Jennifer de los Angeles; Mashal Tahirkheli; Daniel Zhao; Wajeeha Razaq Background: In patients with hormone receptor-positive metastatic breast cancer, palbociclib has been shown to improve overall survival and progression-free survival (PFS) when...

...Uwe Güth; Constanze Elfgen; Giacomo Montagna; Seraina Margaretha Schmid Background: Previous data showed that distant metastatic breast cancer (MBC) might be curable in up to 3% of the cases in selected patients, mostly young, with good performance status and with low-volume metastatic disease...

...Yasuyuki Kojima; Reiko Yoshie; Hisanori Kawamoto; Arata Shimo; Tomoko Uejima; Tsuguo Iwatani; Ai Motoyoshi; Yoshihide Kanemaki; Narikazu Boku; Koichiro Tsugawa Background: In treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the efficacy of capecitabine...

...Guido Giordano; Antonio Febbraro; Erica Quaquarini; Anna Turletti; Rebecca Pedersini; Mimma Raffaele; Federica Villa; Rosalba Rossello; The Italian Eribulin Working Group Liver metastases are very common in metastatic breast cancer (MBC); current treatments for these lesions are based on systemic...

...Raffaele Nettuno; Carmine Menditto Eribulin, a non-taxane inhibitor of microtubule dynamics, is approved for the treatment of metastatic breast cancer patients after progression with anthracyclines and taxanes. Nevertheless, to our knowledge, information on its use in dialytic patients...

... cancer. Chemotherapy 2017; 62: 71–79. 5. Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D’Andrea GM, Lake DE, Choi J, Norton L, Hudis CA: A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin...

... and safety of eribulin in a real-world population of metastatic breast cancer (MBC) patients and to identify possible predictive factors of progression-free survival (PFS) and objective response. Methods: We retrospectively analyzed 71 eribulin-treated MBC patients. Best response rate, PFS, and adverse...

... receptor-positive (ER+) metastatic breast cancers express mutations within the ER ligand-binding domain. While most studies focused on the constitutive ER signaling activity commonly engendered by these mutations selected during estrogen deprivation therapy, our study was aimed at investigating distinctive...

... for metastatic breast cancer patients. In order to confirm that S-1 is noninferior to taxane regarding overall survival, and that S-1 is superior regarding HRQoL, the Selection of Effective Chemotherapy for Breast Cancer (SELECT BC) trial was conducted in Japan [ 16 ]. The trial demonstrated the noninferiority...

...Pavani Chalasani The treatment landscape for hormone receptor-positive metastatic breast cancer continues to evolve as the molecular mechanisms of this heterogeneous disease are better understood and targeted treatment strategies are developed. Patients are now living for extended periods of time...

... exemestane are indicated for hormone receptor-positive, HER2/neu-negative metastatic breast cancer (MBC), in menopausal women without symptomatic visceral disease after recurrence or progression following aromatase inhibitors. But everolimus efficacy as late treatment has not been explored. Methods: Sixty...

...Xavier Durando; Florence Dalenc; Catherine Abrial; Marie-Ange Mouret-Reynier; Pauline Herviou; Fabrice Kwiatkowski; Philippe Chollet; Henri Roche; Emilie Thivat Objective: This study is a longitudinal follow-up of metastatic breast cancer patients treated with ixabepilone as first-line chemotherapy...

..., ABL, PDGFR-α and -β, KIT, and DDR. In solid tumors, it inhibits proliferation and invasiveness and facilitates higher intratumoral cytotoxic drug concentrations. Vinorelbine has good tolerability and efficacy in metastatic breast cancer (MBC). This study evaluates the safety and efficacy of imatinib...

...P. Follana; J. Barrière; E. Chamorey; R. Largillier; B. Dadone; V. Mari; J.M. Hannoun-Levi; M. Marcy; B. Flipo; J.-M. Ferrero Background: Elderly patients with metastatic breast cancer have a prognosis and outcome that may be dependent on a host of factors. Patients and Methods: We retrospectively...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Breast cancer biopsy Breast cancer phenotypes Metastatic breast cancer Receptor change Receptor discordance Recurrent breast cancer Breast cancer is the most...

... improves the efficacy of standard first-line therapy in locally recurrent/metastatic breast cancer (LR/mBC). The benefit of bevacizumab seen in patients with TNBC appears similar to that observed in the overall population. We conducted an exploratory analysis of patients with TNBC treated in the single-arm...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Trastuzumab HER2 Lapatinib Metastatic breast cancer Clinical practice Brain metastases Chemotherapy 11 08 2011 12 08 2011...

...J.M. Ferrero; R. Largillier; C. Michel; V. Amiot; G. Milano; C. Hébert; V. Mari; A. Courdi; A. Figl; P. Follana; J. Barrière; E. Chamorey Background: Despite current treatment options, metastatic breast cancer (MBC) remains essentially incurable, requiring research on new drugs or combinations...